Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
Marshall Wace
AddedFeb 13, 2024
UpdatedJul 16, 2026
Marshall Wace

Marshall Wace

Operating

Marshall Wace LLP, a leading UK-based hedge fund company, founded in 1997.

Location
London, Greater London, GB
Founded
1997
Firm
Compare
Portfolio
Fundraising
Employees
Website

Marshall Wace LLP is a prominent UK-based hedge fund company founded in 1997 by Paul Marshall and Ian Wace. The firm focuses on global alternative investments, managing assets worth $64 billion as of January 2022. Marshall Wace typically invests in later-stage rounds, including Series B, C, D, and beyond, as well as post-IPO equity and private equity rounds.

Notable portfolio companies include Circle, Flywire, and Varo Bank. The firm is led by key decision-makers Paul Marshall, the Chairman and CIO, and Ian Wace, the CEO and Chief Risk Officer. Marshall Wace emphasizes a disciplined and innovative approach to investment, leveraging a diverse and talented team to deliver strong returns for its clients. The firm also offers unique value-add services, fostering a rigorous and creative investment environment.

Marshall Wace - Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments30
Current Portfolio Count26
Total Portfolio Exits0

Top Investment Stages

Series B8 (36.4%)
Series C5 (22.7%)
Series D4 (18.2%)
Post Ipo Equity3 (13.6%)
Private Equity2 (9.1%)

Stage Mix

Series B 36%Series C 23%Series D 18%Post Ipo Equity 14%Private Equity 9%

Concentration shown as share of disclosed investments by stage.

Recent Investments

OnCusp Therapeutics logo

OnCusp Therapeutics

Parse Biosciences logo

Parse Biosciences

SAB Biotherapeutics logo

SAB Biotherapeutics

BlueWhale Bio logo

BlueWhale Bio

Beta Bionics logo

Beta Bionics

Adarx Pharmaceuticals logo

Adarx Pharmaceuticals

Prognos Health logo

Prognos Health

Karyopharm Therapeutics logo

Karyopharm Therapeutics

TRM Labs logo

TRM Labs

Neurolens logo

Neurolens

Elektrofi logo

Elektrofi

Circle logo

Circle

ConSensys Ventures logo

ConSensys Ventures

Metagenomi logo

Metagenomi

Lukka logo

Lukka

Accelerant logo

Accelerant

Tipalti logo

Tipalti

Varo Bank logo

Varo Bank

Inbrace logo

Inbrace

Asher Bio logo

Asher Bio

Neurogastrx logo

Neurogastrx

Amylyx Pharmaceuticals logo

Amylyx Pharmaceuticals

Forge Biologics logo

Forge Biologics

Flywire logo

Flywire

Century Therapeutics logo

Century Therapeutics

Marshall Wace - Classification

Also Known As
  • Marshall Wace LLP
NAICS
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 523900Other Financial Investment Activities
  • 523990All Other Financial Investment Activities
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 6700Holding And Other Investment Offices
  • 6720Investment Offices
  • 6722Management Investment Offices, Open-end
ISIC
  • 6619Other activities auxiliary to financial service activities
Show 2 more industry codes
NAICS
  • 525000Funds, Trusts, and Other Financial Vehicles
SIC
  • 6000Depository Institutions